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ABSTRACT 
Skeletal muscle cells are highly specialised in order to accomplish their function. During 
development, the fusion of hundreds of immature myoblasts creates large syncytial 
myofibres with a highly ordered cytoplasm filled with packed myofibrils. The assembly and 
organisation of contractile myofibrils must be tightly controlled. Indeed, the number of 
proteins involved in sarcomere building is impressive, and the role of many of them has 
only recently begun to be elucidated. 
Myotilin was originally identified as a high affinity α-actinin binding protein in yeast two-
hybrid screen. It was then found to interact also with filamin C, actin, ZASP and FATZ-1. 
Human myotilin is mainly expressed in striated muscle and induces efficient actin bundling 
in vitro and in cells. Moreover, mutations in myotilin cause different forms of muscle 
disease, now collectively known as myotilinopathies. In this thesis, consisting of three 
publications, the work on the mouse orthologue is presented. First, the cloning and 
molecular characterisation of the mouse myotilin gene showed that human and mouse 
myotilin share high sequence homology and a similar expression pattern and gene 
regulation. Functional analysis of the mouse promoter revealed the myogenic factor-binding 
elements that are required for myotilin gene transcription. Secondly, expression of myotilin 
was studied during mouse embryogenesis. Surprisingly, myotilin was expressed in a wide 
array of tissues at some stages of development; its expression pattern became more 
restricted at perinatal stages and in adult life. Immunostaining of human embryos confirmed 
broader myotilin expression compared to the sarcomeric marker titin. Finally, in the third 
article, targeted deletion of myotilin gene in mice revealed that it is not essential for muscle 
development and function. 
These data altogether indicate that the mouse can be used as a model for human 
myotilinopathy and that loss of myotilin does not alter significantly muscle structure and 
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function. Therefore, disease-associated mutant myotilin may act as a dominant myopathic 
factor. 
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REVIEW OF THE LITERATURE 
The theme of this thesis is the analysis of the sarcomeric protein myotilin, which is mainly 
expressed in and whose most important function associates with muscle tissue. Therefore, in 
this review of literature the main aspects of cytoskeleton are described with emphasis 
directed towards striated muscle, including its development. Since mutations in myotilin 
can cause myopathies, the main aspects of hereditary myogenic muscle diseases and the role 
of myotilin in those diseases are described. 
1. The eukaryotic cytoskeleton 
Eukaryotic cells maintain their shape through the cytoskeleton. Far from being a static 
backbone of the cell, the cytoskeleton is essential for a number of vital cellular processes, 
such as the internal movement of organelles, cell locomotion, cell division and muscle 
contraction. In order to accomplish these tasks, three types of protein filaments have 
evolved: microtubules, intermediate filaments and microfilaments. All these filaments are 
built from subunits that can be quickly added and removed, thus creating a highly dynamic 
network of continuously rearranged polymers. 
1.1. Microtubules 
Microtubules are hollow tubes, 24 nm in diameter, made up of tubulin subunits [1, 2]. They 
aid in several types of cellular movements, such as chromosome alignment and separation 
during mitosis, the transport of proteins, vesicles and organelles within the cytoplasm, 
neurite outgrowth and the movement of cilia and flagella. The microtubule subunit is a 
heterodimer of α- and β-tubulin. The longitudinal head-to-tail arrangement of subunits 
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forms a linear protofilament. Lateral interactions between adjacent subunits allow side-by-
side association between the protofilaments, to create the wall of the microtubule. 
Typically, there are 13 protofilaments in each microtubule that are slightly staggered to 
form a spiralling structure. In some particular cases, like in centrioles or in cilia and flagella, 
a more complex structure is generated by the fusion of a second (doublet microtubule) and 
third (triplet microtubule) tubule, made of only 10 protofilaments, to the first microtubule 
[3]. Each tubulin subunit binds two molecules of GTP. One GTP-binding site, located in α-
tubulin, binds GTP irreversibly and does not hydrolyse it, whereas the second site (called 
the exchangeable site), located on β-tubulin, binds GTP reversibly and hydrolyses it to 
GDP. Subunits containing GTP-β-tubulin polymerise into the microtubule and form the so-
called GTP-cap which stabilises the structure. Until polymerisation proceeds faster than 
GTP hydrolysis, the microtubule grows. When GTP is converted to GDP before new 
subunits can be added, the microtubule becomes unstable and depolymerises rapidly. 
Microtubules display structural polarity: addition of subunits occurs preferentially at one 
end, designated as the (+) end, whereas the opposite (-) end is in close proximity with the 
nucleation centre, the centrosome. The centrosomes are rich in γ-tubulin, a third tubulin that 
is not part of the microtubules but is essential for their assembly. 
1.2. Intermediate filaments 
Intermediate filaments (IFs) are made from fibrous proteins encoded by a superfamily of 
more than 50 genes [4]. Five classes of IF proteins are recognised: one that comprises 
nuclear lamins, and four groups of cytoplasmic filaments. Lamins form a network of 
filaments on the inner surface of the nuclei (the so-called nuclear lamina) and create a 
structural scaffold for the nuclear envelop. They undergo regulated disassembly during 
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mitosis. Cytoplasmic IFs include acidic and basic cytokeratins, neurofilament triplet 
proteins, and type III proteins, such as vimentin and desmin. Many of these proteins are 
expressed in a tissue-specific manner: cytokeratins can be divided in “hard” and “soft” 
types, expressed in epithelia and hair, respectively; desmin is specifically expressed in 
muscle cells [5], whereas vimentin is also found in other mesenchymal cells, as well as in 
muscles; other muscle-associated IF proteins include synemin and nestin [6, 7]. Neurons 
have their own set of IF proteins. Intermediate filaments can be homo- or hetero-polymers. 
Subunits consist of two globular ends and a central α-helical rod that mediates dimer 
formation. Two such dimers associate in an anti-parallel fashion to form tetramers. Finally, 
tetramers associate head-to-tail and side-by-side, thus creating the final intermediate 
filament. The main role of IFs is to provide mechanical support to the cells, especially at 
cell-cell and cell-extracellular matrix contacts. Indeed, they are relatively stable and 
resistant to solubilisation. In skeletal muscle cells, IFs link myofibrils among them and to 
the sarcolemma and the nuclei. However, there is evidence that they can perform other 
functions as well.  
1.3. Microfilaments 
Microfilaments are polar, helical double strands consisting of a string of actin monomers, 
from few nanometres to several centimetres long. They are the thinnest filamentous 
structures within a cell, measuring only 5-10 nm in diameter. Actin is the most abundant 
protein of a eukaryotic cell, representing approximately 5% of the total protein content. 
Rapid polymerization and depolymerisation of actin filaments (a phenomenon known as 
treadmilling) occurs via binding and hydrolysis of ATP: free monomers bind ATP and are 
incorporated onto the barbed (fast growing) end of the filament; ATP is then hydrolysed to 
ADP and Pi. Dissociation of ADP-actin at the opposite pointed end causes disassembly of 
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the filament [8]. When association rate of G-actin at the barbed end and off rate at the 
pointed end are balanced, a steady-state is reached. Treadmilling is essential during cell 
motion: the barbed end faces the cell membrane at the leading edge, while the pointed end 
is at the rear. The coordinated action of a number of regulating proteins controls actin 
turnover [9, 10]. Capping proteins block barbed end growth. In addition, some of them 
possess severing activity, thus generating new filament ends. Members of the actin 
depolymerising factors (ADF) family can bind both F- and G-actin and induce rapid 
depolymerisation of filaments, by increasing the pointed-end off-rate. ADFs can severe 
filaments, too. The Arp2/3 complex is a seven-protein complex that is able to nucleate new 
branches on pre-existing actin filaments. Finally, profilin acts as a nucleotide exchange 
factor, by promoting the substitution of ATP for ADP on G-actin; the ATP-actin-profilin 
complex then associates to barbed ends, thus elongating the filament. 
Actin filaments organize to form two types of higher-order structures: bundles and gel-like 
networks. In bundles, several actin filaments are held together by bundling proteins [11, 
12]. Fimbrin is a ubiquitous cross-linking protein with two adjacent actin-binding sites, so 
that it bundles actin filaments in tightly packed arrays such as in filopodia, spike-like 
projections of the plasma membrane that allow a cell to explore the environment in the 
direction of migration. Looser bundles are assembled by α-actinin in stress fibres and focal 
contacts [13]. Stress fibres are contractile bundles of actin and myosin-II filaments ending at 
focal contacts underneath the plasma membrane, where they anchor the cell to the 
extracellular matrix through integrins. Alpha-actinin is also involved in sarcomere 
organisation in muscle cells. Another bundling protein, villin, helps align actin filaments in 
microvilli, the finger-like extensions of the plasma membrane that greatly increase the 
absorptive surface of many epithelial cells. Cross-linking proteins that have a long, flexible, 
or bent connection between their two actin-binding sites tend to form actin webs or gels, 
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rather than bundles. Filamin cross-links F-actin into a network of filaments oriented 
approximately at right angles. An example is found in lamellipodia, sheet-like extensions of 
the cell membrane that help the cells move over a solid substrate. Spectrin is generally 
found as a tetramer (α2β2) on the inner surface of the plasma membrane, where it organises 
the cortical actin cytoskeleton that is needed to maintain membrane integrity. In addition to 
the cortex cytoskeleton, cells have a cytosolic three-dimensional actin network that is linked 
to the cell membrane by different anchoring proteins: filamin in platelets, dystrophin in 
muscle cells, ERM (Ezrin, Radixin, and Moesin) proteins in epithelial cells. This cytosolic 
actin web fills the cytoplasm and gives cells their shape. 
The above depicted picture is a very simplified view of the cell cytoskeleton. Several other 
proteins are involved in its organisation and function, including motor proteins that drive 
transport along filaments, membrane proteins that link the intracellular to the extracellular 
environment, enzymes that trigger signalling cascades leading to cytoskeleton 
rearrangements, and so on. In addition to that, different isoforms or different members of 
the same protein family can exert similar or slightly different functions in a cell type-
specific manner. 
2. Muscle cell cytoskeleton 
As noted above, contractile units (the stress fibres) are formed in non-muscle cells by 
assembling actin and myosin filaments with the assistance of α-actinin. A very specialised 
actomyosin cytoskeleton has developed in muscle cells. Vertebrate muscles are divided into 
three categories according to structural and functional properties: (1) smooth muscles 
contain a loosely organised contractile apparatus, while (2) cardiac and (3) skeletal muscles 
are both characterised by a striated appearance, revealing the presence of highly ordered 
structures, and are therefore called striated muscles. A fourth class of contracting cells is 
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represented by myoepithelial cells, which are found surrounding the secretory epithelium of 
glands. Their contractile activity forces secretions into the excretory duct of the gland. 
2.1. Smooth muscle 
Smooth muscles surround and control the involuntary movements of internal organs such as 
the large and small intestines, the uterus, and blood vessels. Smooth muscle cells contain 
loosely organised contractile bundles of actin (thin) and myosin (thick) filaments, non-
uniform in length, which are attached to dense bodies in the cytoplasm and to dense plaques 
at the cell membrane [14, 15]. Dense bodies contain α-actinin and are also associated with a 
cytoplasmic cytoskeleton composed of desmin filaments and non-muscle actin filaments. 
Although highly ordered arrays of contractile units are not present, an approximately 
regular distribution of dense bodies has been observed [16]. Similarly, dense plaques show 
a characteristic, periodic banding pattern and are enriched in the proteins vinculin and talin, 
which bind to membrane proteins in the plaque and to α-actinin, thereby attaching actin 
filaments to membrane adhesion sites. Such an integrated lattice of cytoskeletal proteins 
provides the smooth muscle cell with the ability to adapt constantly to changes in cell 
length. The regulation of actin-myosin contraction in smooth muscle is regulated primarily 
by phosphorylation of one of the myosin light chains, called the regulatory light chain [17]. 
Its phosphorylation promotes the assembly of myosin into filaments and increases myosin 
ATPase activity, enabling contraction to proceed. The enzyme that catalyzes this 
phosphorylation, called myosin light-chain kinase, is itself regulated by association with the 
Ca2+-binding protein calmodulin [18, 19]. Increases in cytosolic Ca2+ promote the binding 
of calmodulin to the kinase, resulting in phosphorylation of the myosin regulatory light 
chain. 
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2.2. Cardiac muscle 
Cardiac muscle [20, 21] resembles skeletal muscle in some ways: it is striated and contains 
the well-organised contractile units known as sarcomeres, which will be described below. 
However, cardiac muscle has a number of unique features. First of all, it is made of single 
cells, each with a single centrally located nucleus. Secondly, the myofibrils of each cell are 
branched. The branches interlock with those of adjacent cardiomyocytes by adherens 
junctions. These strong junctions enable the heart to contract forcefully without ripping the 
fibres apart. Another peculiar characteristic of cardiac muscle is represented by dark lines 
dividing adjacent cells: the intercalated discs. At the intercalated disc the cell membranes of 
two adjacent cardiac muscle cells are extensively intertwined and bound together by 
adherens junctions and desmosomes. Through these junctions, myofibrils from the two cells 
are locked together. At the same time, gap junctions and other ion channels provide a 
cytoplasmic connection between cells [22]. All these contacts stabilise the relative positions 
of adjacent cells and allow ions and small molecules to move from one cell to another. This 
arrangement creates a direct mechanical and electrical coupling between contiguous cells, 
leading to a synchronised contraction of the entire tissue. 
2.3. Skeletal muscle 
2.3.1. Structure and function 
Skeletal muscles connect the bones and are used by vertebrates to move. They are 
characterised by an extremely ordered assembly of contractile structures. A skeletal muscle 
comprises a bundle of muscle cells, or myofibres. A typical muscle cell is cylindrical, large 
(1 millimetre to few centimetres in length and 10-50 μm wide) and multinucleated 
(containing as many as 100 peripherally located nuclei), arising from the fusion of several 
15
separate cells. A myofibre is packed with myofibrils, bundles of filaments that extend the 
length of the cell. Myofibrils are further subdivided into alternating light and dark bands, 
which are aligned along the length of the muscle cell, giving the myofibre a striated 
appearance under a light microscope. Closer examination reveals that the dark bands, called 
A-bands, are bisected by a darker region, the M-line, while the light bands, called I-bands, 
are bisected by a different dark line, called the Z-disc. The segment from one Z-disc to the 
next, consisting of two halves of an I-band and one central A-band, is termed a sarcomere 
[23]. A chain of sarcomeres constitutes a myofibril. Force generation is driven by sliding of 
actin and myosin filaments and is triggered by an electric pulse coming from a nerve cell. 
This signal propagates into the muscle through a series of sarcolemmal invaginations, 
known as T-tubules that reach and surround each myofibril. The link between the 
generation of an action potential in the sarcolemma and the start of contraction occurs at the 
triads, specialised structures composed of a T-tubule with sarcoplasmic reticulum on either 
side. On reaching a triad, an action potential triggers the release of Ca2+ from the cisternae 
of the sarcoplasmic reticulum into the cytosol. Ca2+ ions bind the thin filament-associated 
protein troponin, which changes conformation and causes the relocalisation of tropomyosin, 
thus allowing the productive interaction of myosin heads and actin filaments [24]. As Ca2+
concentration rapidly returns to baseline values, troponin and tropomyosin regain their 
original position, blocking contraction. Skeletal muscle fibres can be divided into fast and 
slow fibres, based on their physiology. Fast (“white”) fibres are larger in size and possess 
high glycogen storages and high glycolytic activity. This gives them the capacity of 
performing extremely rapid contractions. Slow (“red”) fibres are smaller, richer in 
myoglobin (hence the dark colour) and have high oxidative metabolism. Distinguishing 
features of slow and fast fibres are their respective wide and narrow Z-discs [25]. The fast 
muscle has a narrow, simple Z-disc that resembles a single zig-zag line connecting the ends 
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of the opposing actin filaments from the adjacent sarcomeres. The wide Z-discs in slow 
muscles comprise three to four zig-zag lines stacked axially. Two closely related genes 
(ACTN2 and ACTN3) encode for the main Z-disc protein, α-actinin, in humans. While 
ACTN2 is expressed ubiquitously in skeletal muscles, ACTN3 is only expressed by fast 
fibres. Intriguingly, approximately 20% of the human population is deficient for ACTN3, 
suggesting that its role may be redundant. However, the null genotype is strongly under-
represented (6%) in sprint athletes, indicating that ACTN3 may have a role in the 
specification and functional properties of fibre type [26].  
2.3.2. The sarcomere 
The sarcomere is the structural and functional unit of skeletal muscle [27]. A low resolution 
view of the sarcomere structure describes alternating dark and light zones. A-bands span the 
length of thick filaments, while I-bands comprise the area corresponding to thin filaments 
alone. Thin filaments are anchored at one end to the Z-disc and interdigitate with thick 
filaments at the other end. Each thick filament is a bipolar structure, surrounded at both 
ends by six thin filaments. When the inhibitory troponin/tropomyosin complex is dislocated 
by Ca2+ binding, myosin heads interact with actin and, by changing conformation, pull thin 
filaments towards the centre of the sarcomere. Because actin is tethered to the Z-discs, this 
movement results in the shortening of the sarcomere while thin and thick filaments slide 
past each other. The power enabling muscle contraction comes from ATP hydrolysis [28] 
through a series of steps known as cross-bridge cycle: as the myosin head is bound to actin, 
ATP enters the catalytic site and induces a conformational change that reduces the affinity 
of the head for actin. This enables the head to hydrolyse ATP to ADP and Pi. Free energy 
from this reaction moves the myosin head to a new position, forward along the actin 
filament, where it binds another actin subunit. This in turn triggers the release of inorganic 
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phosphate which causes the myosin head to return to its starting position, pulling the actin 
filament. After nucleotide exchange, the head is ready for another cycle. The net result of 
repeated cycles is that myosin walks on the thin filament. 
A plethora of accessory proteins assist in sarcomere assembly and function. According to 
the four filaments model (figure 1), the giant proteins titin (~3 MDa) and nebulin (800 kDa) 
act as rulers on which thick and thin filaments align [29, 30]. Titin, spanning half 
sarcomere, is tightly associated with the thick filaments via its carboxy- (C-) terminal 
portion. It is mainly composed of repeated fibronectin-III (FN-III) and Ig-like globular 
domains (overall, there are over 200 in one titin molecule) that give to the entire protein the 
appearance of a long necklace dotted with pearls. These repeats are organised into different 
patterns called super-repeats. Non-repetitive regions between FN-III and Ig domains, 
account for approximately 10% of the entire sequence: a kinase-like domain called titin-
kinase is located near the C-terminus, in proximity of the M-line. A unique region with 
spring-like properties, designated the PEVK segment (as it is rich in proline, glutamate, 
valine and lysine residues) confers elasticity to the entire molecule [31]. Due to the PEVK 
domain, titin behaves as an extensible spring. This is crucial in order to allow sarcomere 
shortening, since titin amino- (N-) end is anchored to the Z-disc, while its C-end is attached 
to the M-line. Finally, four to seven alternatively spliced 45-aminoacid repeats (termed Z-
repeats) in the N-terminal region are thought to be responsible for different Z-disc width in 
different types of muscles. 
Nebulin associates with the thin filament system and is thought to be what titin is for thick 
filaments: a template for correct positioning. Its variable C-terminal end inserts into the Z-
disc, while the N-terminal portion is located near the free end of actin, within the A-band 
[30]. In contrast to titin, whose Z-disc region spans the entire Z-line (thus overlapping with 
the corresponding titin region from an adjacent sarcomere), nebulin only enters a small 
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portion of the Z-disc. Similarly to titin, nebulin structure is highly modular, with 185 
repeated domains (modules) arranged in super-repeats. In particular, the central modules 
M9-M162 are responsible for binding to actin, troponin and tropomyosin, whereas the 
amino-terminal M1-M8 unique repeats bind to the pointed end capping protein 
tropomodulin [32]. In addition to their well-established structural roles, titin and nebulin 
also have other functions, which have only recently begun to be elucidated. For example, 
there is evidence that nebulin may regulate contraction, by controlling access of myosin 
heads to the actin filaments. Moreover, nebulin has an SH3 domain, which may participate 
in signal transduction [33]. Titin, on the other hand, has a serine/threonine kinase domain 
that has been shown to phosphorylate T-cap/Telethonin, a Z-disc protein. It is believed that 
this phosphorylation regulates myofibril assembly [34]. 
CapZ is a dimeric Z-disc protein which binds to and caps the barbed end of F-actin, 
facilitating nucleation of nascent thin filaments [23]. It also interacts with α-actinin. 
Tropomodulin, as already mentioned, binds to the opposite (pointed) end of F-actin, where 
it forms a complex with tropomyosin and nebulin. Tropomyosin is a coiled-coil protein that 
bonds head-to-tail to form a long helical filament wrapped around F-actin [35]. Together 
with troponin, tropomyosin forms the Ca++-sensitive molecular switch that permits muscle 
contraction (see above). Troponin is a three-protein complex: troponin C is the subunit that 
actually binds Ca++ ions, whereas troponin I inhibits the actomyosin ATPase activity and 
troponin T binds to tropomyosin, thus linking the troponin complex to the thin filament 
[24]. Upon Ca++ binding, troponin C removes troponin I-mediated inhibition and, through 
troponin T, releases steric hindrance determined by tropomyosin, thereby allowing the 
formation of functional actin-myosin cross-bridges. 
Thick filaments are made of several myosin molecules grouped together to form highly 
regular bipolar structures, with head domains sticking out from the filament at both ends 
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[23]. Tails with antiparallel orientation overlap in the central bare zone. An individual 
myosin molecule is a six-polypeptide complex made of two heavy chains and four light 
chains. The heavy chains C-terminal halves are associated to form a coiled-coil rod domain, 
while the N-termini are folded in globular heads which are responsible for actin binding and 
force generation [36]. Two pairs of “regulatory” and “essential” light chains are associated 
to the heavy chain heads. In striated muscles, light chains do not participate in regulation of 
myosin enzymatic activity, rather they stabilise the structure of the complex. Removing 
light chains has a great impact on sliding velocity. Thick filament-associated proteins 
include myosin-binding proteins (MyBP) -C and –H [37]. They are composed of repeated Ig 
and FN-III domains and are believed to regulate the thickness of the thick filament by cross-
linking myosin filaments and by interaction with titin [38].  
The M-band (or M-line) is the central region of the sarcomere, where thick filaments are 
fastened together. It is crucial for correct alignment of the thick filament system [39]. 
Indeed, its main role may be to prevent or reduce misalignment of thick filaments during 
contraction, caused by random force imbalance between adjacent myosin filaments. 
Myomesin and M-protein (also called myomesin-2) are the main components of the M-band 
[40, 41]. They bridge myosin filaments and anchor titin at the centre, creating a complex 
network of stabilising interactions. 
The functional equivalent of the M-line at the sarcomere ends is the Z-disc (also called Z-
band or Z-line; Figure 2) named after its zig-zag appearance in electron micrographs [25, 
42, 43]. It links actin and titin filaments from adjacent half sarcomeres into a lattice 
connected by α-actinin, a rod-shaped bipolar dimer with actin-binding sites at each end. 
Antiparallel actin filaments from the two adjacent sarcomeres overlap within the Z-disc, 
forming a square lattice such that every actin filament from one side is surrounded by four 
filaments from the opposite side. In addition to actin, α-actinin is also able to cross-link 
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antiparallel titin filaments, by binding to the Z-repeats. The best known role of the Z-disc is 
to transmit tension through successive sarcomeres along the myofibril. However, the 
presence of many other proteins argues in favour of additional functions for the Z-disc, in 
particular in signal transduction and in mechanical connection with the sarcolemma. Recent 
reports point to an active role of the Z-disc in sensing mechanical stress and inducing 
changes in gene expression accordingly [44]. Many Z-disc proteins belong to the family of 
PDZ/LIM proteins which are characterized by a PDZ and one or more LIM protein-protein 
interaction domains. This suggests that these proteins may be involved in the formation of 
large signalling complexes [43]. Five Z-disc-associated PDZ/LIM proteins have been 
described so far: ALP (Actinin-associated LIM Protein), ZASP (Z-band Alternatively 
Spliced Protein, also termed Cypher or Oracle; refs. [45, 46]), Enigma, ENH (Enigma-
Homologue protein) and CLIM1 [27, 43]. A separate subfamily of LIM-only proteins that 
localise to the Z-disc has been identified, comprising FLH-1, -2 and –3 (Four and a Half 
LIM domains), Zyxin, MLP (Muscle LIM Protein). Other important signal transducers have 
been found within the Z-disc, including PKCε (protein kinase C epsilon), the calcium-
dependent phosphatase calcineurin (also known as protein phosphatase 2B), the calsarcins 
[47], myopodin, phosphodiesterase 5A, PAK-1 (p21-activated kinase-1) and ArgBP2 (Arg-
binding protein 2). An additional set of Z-disc proteins is involved in protein ubiquitination 
and degradation [43]: MuRF1(muscle-specific RING finger 1) and MAFbx (muscle atrophy 
F box protein) are ubiquitin ligases, whereas the calpains are intracellular non-lysosomal 
Ca++-dependent cysteine proteases [48]. 
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Figure 1. Electron micrograph (upper) and enlarged schematic drawing (lower) of a 
sarcomere, showing the four filament (actin-myosin-titin-nebulin) system and morphologic 
regions (A- and I-bands, M-line and the Z-disc).  indicates the elastic region of titin 
(adapted from Gregorio et al. [29]). 
I-band
A-band
MZ
22
Figure 2. Schematic drawing of the Z-disc and its molecular components (adapted from 
Frank et al. [43]). 
2.3.3. The sarcolemma connection 
An IF-based network mediates the mechanical and functional linkage of the contractile 
apparatus to the rest of the cell, in particular to the sarcolemma. Desmin is the predominant 
IF protein interconnecting Z-discs between them and to the sarcolemma. Costameres are Z-
disc-linked subsarcolemmal structures, representing the cortical cytoskeleton of a muscle 
cell [49]. They have been described as the muscle-specific equivalent of focal contacts. 
Indeed, both structures are enriched in vinculin, talin, α-actinin, spectrin and integrins. The 
available data suggest that costameres may function to laterally transmit contractile forces 
from sarcomeres across the sarcolemma to the extracellular matrix and ultimately to 
nebulin
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neighbouring muscle cells [50]. This would be useful for maintaining uniform sarcomere 
length between adjacent cells and for minimizing shear stress imposed on the sarcolemma. A 
growing number of proteins forms the intricate costamere/sarcolemma network, whose 
importance is highlighted by the variety of muscular disorders associated with loss of its 
function (see section 5. Muscular Disease). The dystrophin-glycoprotein complex (DGC) is 
a transmembrane multiprotein complex that links cortical γ-actin to the extracellular protein 
laminin-2 [51, 52], as illustrated in figure 3. The DGC includes dystrophin, α- and β-
dystroglycan [53, 54], four (α-, β-, γ-, and δ-) sarcoglycans [55, 56], α- and β-dystrobrevin, 
sarcospan and syntrophins. Caveolin-3 and nNOS (neuronal nitric oxide synthase) are also 
associated to the complex. While α- and γ-sarcoglycans are mainly expressed in striated 
muscle, β-, δ- and two additional (ε- and ζ-) sarcoglycans are more broadly expressed. 
Indeed, variants of the DGC are also present in non-muscle cells, where they connect the 
cortical actin cytoskeleton to the extracellular matrix [57]. Within the complex, dystrophin 
is the actual actin binder, through its aminoterminal actin-binding domain [58]. An 
additional actin binding site is located within the central rod domain, composed of 24 
spectrin-like repeats. Near the C-terminus, the cysteine-rich domain binds the 
transmembrane protein β-dystroglycan, which in turn binds α-dystroglycan. The extreme C-
terminal region mediates interaction with the syntrophins. The sarcoglycans are believed to 
stabilise the whole complex, as loss of any one of these proteins leads to the destruction of 
the entire DGC [59, 60]. The second major connection to the extracellular environment is 
mediated by integrins [61], a large family of ubiquitously expressed membrane proteins 
consisting of αβ heterodimers. Different α and β subunits are expressed in different tissues. 
Cell signalling originating from integrin engagement involves activation of selected protein 
kinases such as ILK (integrin-linked kinase) and FAK (focal adhesion kinase). 
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Figure 3.  Schematic drawing of the dystrophin-glycoprotein complex, mediating direct 
connection between the cell cytoskeleton and the extracellular environment 
The muscle-specific isoform of filamin, Filamin C (also known as filamin-2 or γ-filamin), is 
localised both at the Z-disc (where it binds FATZ-1/calsarcin-2 and myotilin) and at the 
sarcolemma (bound to the DGC via γ- and δ-sarcoglycan and to β1-integrin subunits). 
Therefore, it provides a direct link between the sarcolemma and the myofibrils and is 
thought to have an important function in signalling between the two compartments [62, 63]. 
As all members of the filamin family, Filamin C is able to cross-link F-actin. 
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3. The Palladin/Myotilin/Myopalladin family 
3.1. Palladin and myopalladin 
Palladin, myopalladin and myotilin form a small family of highly homologous actin-binding 
proteins with Ig-like domains [64]. Palladin is the most widely expressed member of this 
family, as it is found in various epithelial and mesenchymal cell types, including smooth 
muscle [65, 66]. Palladin is expressed in multiple isoforms, ranging in size from 30 to 200 
kDa, mainly due to alternative initiation and termination of transcription and also to 
alternative splicing. The longest, 200 kDa isoform is exclusively expressed in skeletal and 
cardiac muscle and comprises five Ig-like C2-type domains homologous to Ig-like domains 
of myotilin and myopalladin, and two proline-rich domains (FPXPP) responsible for the 
binding of Ena/VASP family proteins. VASP proteins are important regulators of actin 
assembly, especially at active sites of actin dynamics, such as lamellipodia, filopodia and 
focal adhesions in non-muscle cells [67]. This implicates palladin in the organisation of the 
actin cytoskeleton [68]. It is thought that palladin may recruit VASP at specific sites of actin 
polymerisation. As a further evidence of its role in actin dynamics, palladin co-localises 
with α-actinin in focal adhesions, cell-cell junctions and stress fibres. The α-actinin binding 
site resides in a short sequence upstream of the three C-terminal Ig-like domains [69]. This 
α-actinin binding sequence is highly conserved also in myotilin. Moreover, palladin 
interacts with ezrin, an important structural component of the cortical actin cytoskeleton 
[66]. 
Myopalladin is a 145-kDa protein most related to palladin, with five Ig-like domains and 
one proline-rich motif [70]. Unlike palladin, its expression is restricted to striated muscles, 
where it mainly localises to Z-discs and I-bands. Myopalladin binds to α-actinin, to the Z-
disc region of nebulin (and its cardiac homologue nebulette) and to the cardiac ankyrin 
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repeat protein (CARP). Interaction with α-actinin and nebulin suggests that myopalladin 
may anchor nebulin to the Z-disc, thus contributing to the building of the sarcomere [33]. In 
line with this, overexpression of myopalladin fragments induces severe disruption of the 
sarcomere. The interaction with CARP suggests a role for myopalladin in mechanic stress 
sensing. CARP is abundantly expressed in the developing heart and is strongly induced in 
stressed skeletal muscle. It is localised both in the nucleus, where it regulates the expression 
of cardiac genes, and in the sarcomeric I-band. Therefore, myopalladin and CARP may act 
as a myofibril-nucleus shuttling complex that controls gene expression in response to 
various stimuli generated in the sarcomere. Recently, myopalladin has been implicated in 
the onset of idiopathic DCM: 4 of 114 patients carried missense mutations at conserved 
sites [71]. 
3.2. Myotilin 
Myotilin (myofibrillar titin-like protein) also known as TTID (TiTin Immunoglobulin 
Domain) was the first member of this small family to be discovered [72, 73]. It was 
originally identified as a novel α-actinin binding partner with two Ig-like domains, that 
localised to the Z-disc [73]. The C2-type Ig-like domains reside at the C-terminal half, and 
are highly homologous to the two most C-terminal Ig domains of palladin and myopalladin 
[74], and more distantly related to Z-disc Ig domains 7 and 8 of titin. By contrast, the N-
terminal part of myotilin is unique, consisting of a serine-rich region with no homology to 
known proteins. Expression in human tissues is mainly restricted to striated muscles and 
nerves [73], although minor expression has also been detected in other organs [72]. In 
muscles, myotilin is predominantly found within the Z-discs, although it has been observed 
at the sarcolemma as well. Myotilin forms homodimers and binds α-actinin [73], actin [75], 
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Filamin C [63], FATZ [76], ZASP [77] and MURF [78] proteins. Self-association is 
mediated by the C-terminal Ig-like domain-containing region of myotilin, whereas binding 
to the EF-hand motifs of α-actinin occurs via the N-terminal sequence and accounts for Z-
disc localisation. The interaction with Filamin C could explain the sarcolemmal localisation 
of myotilin and provides a novel link between the cell membrane and the sarcomere. 
Filamins have a modular structure, with 24 Ig-like domains following an N-terminal actin-
binding domain. The muscle-specific Filamin C isoform has a unique 78-aminoacid 
insertion within Ig-like domain 20, which appears to be responsible for Z-disc targeting. 
The interaction with myotilin was mapped to a region corresponding to domains 19-21. 
However, myotilin was later shown to interact with Filamins A and B, as well [76]. The 
filamin binding sites of myotilin have been located in the two Ig-like domains [63] and in 
the N-terminal half [76]. 
Myotilin induces the formation of actin bundles in vitro and in non-muscle cells [75]. The 
Ig-like domains most probably mediate actin binding, as a C-terminal myotilin construct 
showed co-localisation with the actin cytoskeleton in transfected cells. However, fragments 
containing Ig-like domains were not sufficient to induce the formation of large actin cables, 
indicating that other parts of myotilin are needed for bundling. Interestingly, a ternary 
complex myotilin/actin/α-actinin can be observed in vitro and actin bundles formed in this 
conditions appear more tightly packed than those induced by α-actinin alone. It was 
demonstrated that myotilin stabilises F-actin by slowing down the disassembly rate. Due to 
its properties, myotilin is likely to play a role in myofibrillogenesis in muscle cells. Indeed, 
ectopic overexpression of either N-terminal or C-terminal truncated myotilin causes the 
disruption of nascent myofibrils and co-accumulation of myotilin and titin in amorphous 
cytoplasmic precipitates [63, 75]. Human myotilin is normally expressed at late stages of 
differentiation, during myofibril alignment. In contrast, titin and α-actinin are expressed 
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much earlier. This suggests that premature expression of myotilin might be deleterious in 
differentiating myoblasts, as indicated by the dramatic reorganisation of the actin 
cytoskeleton in transfected non-muscle cells. In mature sarcomeres, wild-type myotilin co-
localises with α-actinin and Z-disc titin, showing the striated pattern typical of sarcomeric 
proteins. 
FATZ-1 (also known as myozenin-1 or calsarcin-2) is a Z-disc-associated protein that binds 
filamin, α-actinin and telethonin [79]. FATZ-1 belongs, together with FATZ-2 and -3, to a 
small family of proteins that interact with calcineurin. Having a similar ultrastructural 
distribution and common binding partners, FATZ-1 and myotilin were hypothesised to 
interact. Indeed, it was shown that full-length, but not truncated, myotilin binds the C-
terminal domain of FATZ-1 and FATZ-2. Interestingly, while myotilin and FATZ-1 co-
localise in the sarcomere, they show a different localisation in transfected CHO cells: 
myotilin induces and decorates actin bundles, whereas FATZ-1 shows a punctuated pattern 
along the stress fibres. However, when co-transfected, myotilin induces the relocalisation of 
FATZ-1 to actin bundles, again indicating that myotilin has a dominant effect on the 
intracellular distribution of its binding partners and therefore has a prominent role in the 
organisation of the cytoskeleton. 
Very recently, our laboratory characterised a specific interaction between myotilin and 
various PDZ/LIM proteins [77]. Myotilin interacts with the PDZ domain of ZASP, ALP, 
CLP36 and RIL via its five C-terminal residues (ESEEL). This C-terminal motif is 
conserved in palladin and myopalladin proteins and is also present in FATZ family proteins. 
Accordingly, all these proteins are able to bind ZASP. Therefore, the myotilin and FATZ 
families form a superfamily of PDZ ligands. The interaction between PDZ domains and 
their ligands is often regulated by phosphorylation: myotilin was shown to be 
phosphorylated by CaMKII in vitro [77]. 
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Considering its binding partners, in vitro properties, timing of expression and its activity in 
cells, myotilin is considered to be a stabiliser of the Z-disc structure. Of note, myotilin, 
Filamin C and α-actinin altogether create a formidable actin cross-linking complex at the Z-
disc. Therefore, loss of normal myotilin function may have dramatic consequences for the 
architecture of the sarcomere. Indeed, myotilin mutations have been identified in families 
showing hereditary myopathies (see below).  
4. Myogenesis 
4.1. Stages of mouse development 
As in all vertebrates, early stages of mouse development involve simple cell divisions from 
the fertilised egg to a 16-cell morula. At this stage, about 3 days post coitum (dpc; or E3), 
as cells continue to divide, the first specialisation occurs: an internal cavity develops and the 
cells from the outer layer, forming the wall of the sphere (the trophectoderm), are 
committed to become extraembryonic tissues. An inner mass of cells, located to one side of 
the cavity, will give rise to the whole of the embryo proper [80]. The cells of the 
trophectoderm make close contact with the wall of the uterus, initiating formation of the 
placenta. Meanwhile the inner cell mass (ICM) grows and begins to differentiate. Part of it 
(the one facing the cavity, known as visceral endoderm, endoblast, or hypoblast) gives rise 
to some further extraembryonic structures, such as the yolk sac, while the rest of it (the 
epiblast) goes on to form the embryo. As the ICM grows, a new cavity appears within it: the 
amniotic cavity. Now the embryo is composed of a simple bilayer of cells that separates the 
amniotic cavity from the yolk sac. At the beginning of the gastrulation (6-7 dpc), a linear 
invagination (the primitive streak) appears on the amniotic surface of the two germ layers. 
Complex movements of epiblast cells towards and through the primitive streak lead to the 
insertion of a new sheet of cells between the epiblast and the hypoblast. At the end of 
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gastrulation, a complete embryo with three germ layers, namely ectoderm, mesoderm and 
endoderm, has formed. The embryo already shows a symmetry. At this stage, the median 
region of the ectoderm thickens and differentiates into the neuroblast, forming a neural 
plate. Its margins then begin to rise (E7.5) and finally fuse along the midline, giving rise to 
the neural tube. Some cells that take part to this movement do not actually fuse, but form 
two columns of cells along both sides of the neural tube, called neural crests. They then 
fragment into several small cell masses, which will generate the ganglia and other cell types 
[81]. Proliferation and differentiation of the neural tube epithelium will eventually 
determine the formation of the whole nervous system. Since its first appearance, the 
cephalic region of the neuroblast is much larger than the rest. This difference is maintained 
in the neural tube, as the rostral portion of it is characterised by large vesicles rather than a 
simple tube. These vesicles represent the primitive brain [82]. At the same time, the 
digestive tract can be identified, as the most dorsal portion of the yolk sac gets engulfed by 
the closure of the lateral margins of the embryo. Differentiation of the various segments of 
the digestive tube leads to the formation of several structures, such as the pharyngeal arches 
(also termed branchial or visceral arches, formed between 7.5 and 9.5 dpc), and later the 
lungs, the liver and the pancreas. In particular, the lungs develop as an outgrowth of the 
foregut (the primordium of the bronchi) that serially bifurcates into progressively smaller 
tubes. 
At E7.5 the heart starts to develop and at E8 the first somites appear in the anterior region. 
At 9-10 dpc the rostral domain of the neural tube closes and the forebrain vesicle subdivides 
into telencephalic and diencephalic vesicles; the limb and tail buds appear. By E13 all major 
organs, including genital and urinary systems, have started to form, and limbs with fingers 
are clearly visible. During late stages of development (E14-E18) the foetus increases in size, 
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skin derivatives (hair and nails) appear, and eyelids close upon the eyes. After 19-20 days of 
gestation, the newborn mouse is delivered [83, 84].  
4.2. Development of striated muscles 
The developmental process leading to muscle formation in vertebrates is complex and 
tightly regulated. The first striated muscle to form is the heart, followed by skeletal muscle, 
which is mainly derived from the somites.  
The first sign of cardiac development is the cardiogenic plate (E7-7.5) that is first found 
cranially outside the embryo [85]. Pre-myocardial cells can be traced by expression of 
NKX2.5, a master gene controlling cardiac development. Then, as the embryo folds, this 
area is brought ventral and caudal to the head. The primitive heart develops at about 7.5 dpc 
from a pair of endocardic veins, which come in contact and fuse at a specific region, just 
caudal of the pharyngeal arches, along the embryo midline. The resultant cardiac tube, 
which already expresses cardiac α-actin, grows unevenly so that different regions can be 
distinguished in the antero-posterior axis: bulbus cordis, ventricle, atrium and the venous 
sinus. Then, the heart tube starts to fold in a way that brings the atrium, which is originally 
posterior to the ventricle, anterior and dorsal. At this stage, the ventricle region extends to 
the right and makes a loop with two segments that will grow out, forming the left and right 
ventricles, separated by a constriction that will develop as the ventricular septum. At about 
the same time (E11), the atrial component of the primary heart tube blows out to form 
morphologically distinct left and right atria, which then become separated by growth of a 
thin muscular wall (the atrial septum). By E12, the development of the four cardiac 
chambers has completed [86]. 
Somites appear at about E8 in the cervical region of the mouse embryo [87], as spheroid 
agglomerates of epithelial-like cells at both sides of the neural tube (figure 4). Formation of 
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new somites proceeds in the cephalo-caudal direction. Cues from the neural tube and the 
notochord, including Wnt, Shh and Notch signals, induce segmentation and epithelialisation 
of the paraxial mesoderm, leading to the formation of the somites. Presumptive muscle 
progenitor cells in the early somite express Pax3 and Myf5 [88, 89] which mediate 
activation of MyoD expression in response to muscle-inducing signals. Each somite then 
differentiates into two subdomains of committed cells: dermomyotome and sclerotome, 
which will yield skin/muscle and bone tissues, respectively. At this stage, muscle-
determined cells (myoblasts) express all the four muscle regulatory factors (MRFs): Myf5, 
MyoD, myogenin and MRF4 (also known as Myf6). The MRFs are transcription factors 
characterised by a helix-loop-helix motif (HLH) that recognises CANNTG sequences 
(called E-boxes) on promoters/enhancers of target genes. They can roughly be divided into 
determination (Myf5 and MyoD) and differentiation (myogenin and MRF4) factors, as the 
former determine the fate of myogenic cells and the latter induce the expression of muscle-
specific genes. Moreover, Myf5 and MyoD are normally considered as acting upstream of 
myogenin and MRF4. However, the scenario is more complex than this: there is a 
significant degree of redundancy among the four MRF activities, as shown by knockout and 
knock-in mouse models [90]. In addition, a great deal of reciprocal induction takes place 
and the MRFs also work in concert with MEF2 family factors. Therefore, it is the entire 
network, rather than a single actor, that is to be considered as the master switch of 
myogenesis [91]. In any case, having four different players with different spatio-temporal 
patterns of expression helps fine-tune muscle differentiation in the various body districts. 
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Figure 4. Schematic representation of somitogenesis. Myotome compartment is coloured 
orange (adapted from Buckingham et al. [92]) 
MRF-expressing cells in the dermomyotome still have a round shape and proliferate 
actively. Soon after, some cells delaminate from the ventral edge of the dermomyotome to 
colonise the central region of the somite and generate the myotome, the precursor of trunk 
muscles. Some cells migrate farther to found muscle masses of the limbs. At this point the 
cells (myocytes) exit the cell cycle and begin to express terminal differentiation genes. The 
first muscle-specific protein, detected at E9, is desmin, followed by titin, actin and myosin, 
and a few hours later by nebulin [5]. These proteins still show a speckled distribution within 
the cells. At day 11, myocytes begin to elongate and acquire a spindle shape, while a 
periodic staining of muscle proteins indicates the formation of the first, immature 
myofibrils. As myogenesis progresses, longer and more organised myofibrils fill the 
cytoplasm and the myocytes begin to fuse, to become multinucleated myotubes. Around 
E14, as myotubes grow longer and larger, myofibrillar proteins acquire the characteristic 
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cross-striated pattern and the nuclei are pushed aside. Mature contractile fibres have fully 
developed to an adult-like structure by 17 dpc, a couple of days before birth. Throughout 
adult life, muscle stem cells (satellite cells) are found under the basal lamina of muscle 
fibres. These Pax3/Pax7/Myf5-positive quiescent cells become activated in response to 
muscle injury, or during post-natal muscle mass growth, and provide a reserve of myogenic 
precursors for muscle regeneration. It has been observed that these same Pax-positive cells 
are present in the dermomyotome during pre-natal development and provide a source of 
muscle cells. Very recently, a pool of Pax7-positive endothelial cells with high myogenic 
potential has been observed in the same compartment as satellite cells [93]. The data 
suggest that this myoendothelial cell population can regenerate damaged muscle with higher 
efficiency than satellite cells and can also replenish the satellite cell pool. In vitro,
myoendothelial cells show multilineage potential in the appropriate conditions and are 
considered as a promising tool for human therapy. 
35
5. Muscle disease 
5.1. Classification of neuromuscular diseases 
Neuromuscular diseases are traditionally classified into three main categories: 1. 
Neurogenic muscle diseases, hereditary and acquired, 2. Disorders of neural transmission 
(myasthenias), hereditary and acquired and 3. Myogenic diseases, with a great number of 
both hereditary and acquired diseases. Given the enormous field and the scope of this thesis, 
only the last mentioned myogenic disease group will be described here. Even within this 
group, I will limit detailed description to those groups of hereditary myogenic diseases into 
which the myotilin-associated dystrophies/myopathies are classified. Although defects of 
striated muscle genes, including myotilin, also manifest themselves as cardiomyopathies, 
heart disease is not covered in this review. Cardiac involvement is mentioned whenever 
associated with skeletal muscle disease. 
Defects in a large number of sarcolemmal, sarcomeric, cytoplasmic, nuclear and 
extracellular proteins cause muscle disease. Pathologists have traditionally divided 
myogenic disorders into two main classes: muscular dystrophies (MD) and non-dystrophic 
myopathies. While MDs show disruption of muscle integrity and necrosis, myopathies are 
characterised by weakness and atrophy, often with intracellular deposits. Even though this 
classification may still have a morphological significance, it has become more and more 
evident during the last decade that it does not hold from a molecular point of view, as 
proteins involved in both types of disorder can be found. Moreover, an overlap of 
phenotypic manifestations is often observed, that contribute to blur the picture of disease 
classification. There is nowadays a tendency to refer to a muscle disease as a specific 
proteino-pathy, and diagnosis is based, whenever possible, on genetic mutational analysis. 
For simplicity, I will here group the diseases by clinical denomination, according to the 
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official journal of World Muscle Society [94]. However, molecular relations and 
classification is also presented. 
5.2. Muscular dystrophy 
The clinical course of MD varies from mild, slowly progressing forms with late onset to 
severe, rapidly wasting congenital myopathies. X-linked MDs include Duchenne (DMD), 
Becker (BMD) and Emery-Dreifuss (EMD) muscular dystrophies. DMD and BMD are both 
caused by mutations in the dystrophin gene and are therefore allelic variants of 
dystrophinopathy [95]. DMD and BMD are the most common genetic muscle disorders, 
with an approximate rate of 1 in 3,000 newborn males. A high proportion of cases is 
represented by de novo mutations, due to the extremely large size of the dystrophin gene 
(about 80 exons spanning over 2.3 Mb). DMD patients suffer a progressive muscle 
weakness that typically causes inability to walk by the age of 12 and eventually leads to 
death because of respiratory or heart failure. BMD is usually less severe and some patients 
can walk throughout their lives. The majority of DMD mutations are deletions which cause 
a reading frameshift in the sequence, leading to a premature stop codon and the synthesis of 
a truncated, non-functional protein. In most cases, nonsense-mediated decay of the mRNA 
and/or degradation of the abnormal protein leads to almost completely negative 
immunostaining for dystrophin. The outcome is that not only dystrophin, but the whole 
DGC is missing from the sarcolemma. Thus, the link between the actin cytoskeleton and the 
extracellular environment is lost. This is thought to be the cause of progressive muscle 
damage from repeated contraction. The milder BMD phenotype is prevalently associated 
with in-frame deletions of the central region of the dystrophin gene, that lead to the 
production of a partially functional protein. The observed correlation between type of 
mutation and phenotype (the “reading frame” hypothesis) suggested that most of the central 
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rod-domain may not be essential for dystrophin function: the intact actin-binding (N-
terminal) and dystroglycan-binding (C-terminal) domains would be enough to restore quasi-
normal muscle functionality. This was indeed shown by microdystrophin transgenic mice, 
in which ectopic expression of miniaturised centrally deleted dystrophins restored muscle 
integrity in dystrophin/utrophin double-knockout mice [96]. The most commonly used 
mouse model for DMD/BMD is the naturally occurring mdx mouse [97], which carries a 
mutation in the dystrophin gene causing total loss of dystrophin protein. Despite striking 
molecular similarities with its human counterpart (fibrosis of muscle tissue, centrally 
nucleated fibres, elevated serum creatine kinase levels) this mouse does not show the 
severity that is typical of the human disease. This is possibly due to compensation by 
overexpression of the dystrophin-related protein utrophin. Therefore, the 
dystrophin/utrophin doubly null mouse represents a better model of DMD from a 
therapeutic point of view. 
X-linked EMD is caused by a deficiency in emerin, an integral protein of the nuclear 
envelope inner membrane [98]. Emerin interacts with lamin A, one of four lamins that line 
the inner surface of the nuclear membrane. Notably, an autosomal form of EMD is linked to 
mutations in the lamin A/C gene. Other nuclear proteins involved in the onset of EMD are 
nesprin-1 and -2 (nuclear envelope spectrin repeat protein) [94]. Thus, EMD is a disease of 
the nuclear envelope. Lamin A/C knockout mice show an EMD-like phenotype [99]. 
Clinically, EMDs are characterised by muscle weakness, cardiac arrhythmia and 
contractures at the joints. Lamin defects are also associated with a number of additional 
muscular and non-muscular disorders, including LGMD1B (see below), Dunnigan-type 
familial partial lipodystrophy, and progeria. The generic terms laminopathy or nuclear 
envelopathy have been introduced to indicate this panel of genetically related diseases. 
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5.3. Congenital muscular dystrophy 
Congenital muscular dystrophy (CMD) is a condition that refers to a spectrum of diseases 
with very early onset, normally already manifest at birth or shortly after. They have 
autosomal recessive inheritance and are clinically and molecularly quite heterogeneous. 
CMDs can be assigned to three major classes based on the genes involved: 
  (I)  Abnormalities of extracellular matrix proteins: laminin-α2 chain of merosin (LAMA2) 
and collagen VI subunits COL6A1, COL6A2 and COL6A3. About one third of patients 
with classical CMD display LAMA2 mutations. Collagen mutations are less frequent. 
  (II)  Defects of sarcolemmal links to the extracellular matrix: integrin α7 chain and several 
enzymes with glycosyltransferase activity: fukutin, POMGnT1, POMT1, POMT2, FKRP 
and LARGE. Thus, mutations hit, either directly (integrin α7β1) or indirectly (loss of 
glycosyltransferase activity leads to defective processing of α-dystroglycan) one of the two 
merosin receptors. These CMDs (muscle-eye-brain disease, Walker-Warburg syndrome, 
Fukuyama MD) are typically associated with brain malformations and mental retardation. 
  (III)  Mutations in an endoplasmic reticulum protein (selenoprotein N1). This relatively 
rare condition is also referred to as rigid spine syndrome. 
Altogether, an emerging theme among factors involved in the pathogenesis of CMD is their 
connection to the extracellular matrix [100]. Despite obvious differences in onset and 
muscle involvement, several CMD forms display a certain degree of overlap with LGMD. 
In fact, some recessive LGMD types are allelic with CMD and the clinical boundaries 
between phenotypes are not so sharp. 
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5.4. Limb-girdle muscular dystrophy 
Limb-girdle muscular dystrophies (LGMDs) are a heterogeneous group of MDs 
characterised by pelvic and/or shoulder girdle musculature weakness. They can be divided 
in two groups by mode of inheritance: there are 7 (3 known genes, 4 mapped but gene not 
identified) currently known autosomal dominant (type 1) and 15 recessive (type 2) LGMDs 
[101], as listed in Table 1. Several LGMD-associated genetic defects have also been 
observed in other muscle diseases, which are therefore considered as allelic disorders. 
5.4.2. Dominant LGMD 
Autosomal dominant LGMDs comprise seven forms, often found in only a few families. 
Typically, mutations lead to the expression of dominant-negative forms of the involved 
proteins. 
LGMD1A is the limb-girdle phenotype of myotilinopathy and is discussed in a separate 
section [see par. 5.8]. LGMD1B is a mild, slowly progressive disease with cardiac 
conduction defects [102]. It is caused by mutations in lamin A/C, the same gene involved in 
autosomal dominant (AD)-EMD. Therefore, LGMD1B and AD-EMD are allelic disorders. 
Actually, lamins A/C are involved in various neuromuscular, cardiac, and lipodegenerative 
diseases [103]. It is not yet clear whether the type of mutation underlies the type of disease. 
Mutations are predicted to perturb the structure of the nuclear envelope. A single mutation 
was found in a family in which three phenotypes were described: EMD, LGMD1B (both 
with cardiac involvement) and pure DCM, suggesting the presence of additional, genetic 
and non-genetic, disease modifiers [104]. 
Caveolin-3 mutations underlie a third dominant form, named LGMD1C. Caveolin-3 is the 
muscle-specific member of the caveolin family of membrane proteins. Caveolins 
oligomerise in certain areas of the cell membrane, and constitute the coating of small 
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membrane invaginations called caveolae, involved in membrane trafficking and cell 
signalling [105]. Caveolin-3 is localised at the sarcolemma where it binds β-dystroglycan (it 
is therefore a member of the DGC) and dysferlin. Mutations in caveolin-3 lead to 
LGMD1C, hyperCKaemia, rippling muscle disease, and an atypical distal myopathy [106]. 
LGMD1C-associated mutant caveolin-3 protein acts as a dominant-negative inhibitor, 
oligomerising with wild-type caveolin-3 and directing these complexes to proteosomal 
degradation. Ultimately, this effect results in an almost complete loss of caveolin-3 
expression. Both knockout and transgenic mice have been described. Lack of caveolin-3 
leads to depletion of caveolae in striated muscles and induces a very mild phenotype with 
evidence of myofibre apoptosis in the soleus and the diaphragm [107]. Loss of caveolae 
seems to cause a defect in targeting of the DCG to lipid rafts, thus altering its normal 
sarcolemmal distribution [108]. Moreover, abnormal T-tubules were observed. On the other 
hand, over-expression of caveolin-3 leads to a DMD-like phenotype with an abnormal 
number of caveolae [109]. The similarity with DMD may be explained by a competition 
between caveolin-3 and dystrophin for β-dystroglycan binding. 
Not all LGMD families with dominant inheritance carry mutations in myotilin, lamin or 
caveolin-3. At least four additional loci, designated LGMD1D to -1G, have been described, 
but the causing genes have not yet been identified [94]. Linkage analysis has restricted the 
candidate areas (6q23 [LGMD1D]  -  7q [LGMD1E]  -  7q32 [LGMD1F]  -  4p21 
[LGMD1G]). 
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Type Gene/Locus Ref. Localisation Allelic disorders 
1A Myotilin [110] Sarcomere MFM; SBM ;Distal myopathy 
1B Lamin A/C [102] Nuclear membrane EMD; Dunnigan’s lipodystrophy; DCM 
1C Caveolin-3 [111] Sarcolemma HyperCKemia; Distal myopathy; Rippling muscle disease; HCM 
1D 6q23 [112] 
1E 7q [113] 
1F 7q32 [114] 
1G 4p21 [115] 
2A Calpain 3 [116] Sarcoplasm/sarcomere Eosinophilic myositis 
2B Dysferlin [117] Sarcolemma Miyoshi Myopathy; Distal anterior myopathy 
2C γ-sarcoglycan [118] Sarcolemma  
2D α-sarcoglycan [119] Sarcolemma 
 
2E β-sarcoglycan [120] Sarcolemma 
 
2F δ-sarcoglycan [121] Sarcolemma DCM 
2G Telethonin [122] Sarcomere DCM; HCM 
2H TRIM32 [123] Sarcoplasm/sarcomere Sarcotubular myopathy 
2I Fukutin-related protein [124] 
Sarcoplasmic 
reticulum CMD1C; WWS; MEB 
2J Titin [125] Sarcomere TMD; DCM; HCM; Edström myopathy 
2K POMT1 [126] Sarcoplasmic 
reticulum WWS; MEB; CMD 
2L Anoctamin 5 [127] Sarcolemma Gnathodiaphyseal dysplasia 
2M Fukutin [128] Golgi WWS; MEB; Fukuyama CMD 
2N POMT2 [129] Sarcoplasmic 
reticulum WWS; MEB; CMD 
2O POMGnT1 [130] Sarcoplasmic 
reticulum WWS; MEB 
Table 1. Gene table of the Limb-Girdle Muscular Dystrophies: autosomal dominant 
LGMD1A-G are listed on grey background color; autosomal recessive LGMD2A-O are 
shown with light-blue background. Allelic disorders are shown for each disease. 
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5.4.1. Recessive LGMD 
Recessive forms account for most LGMD cases. A growing number of genes is involved in 
the onset of autosomal recessive LGMDs. Mutations normally cause a loss of normal 
protein function. 
LGMD2A (calpainopathy) is one of the most common LGMDs (approximately one third of 
all cases). In contrast to sarcoglycanopathies (see below) and other LGMDs, muscle 
degeneration in LGMD2A is not a consequence of sarcolemma disruption. The DGC is 
functional and no or very little Evans-blue uptake, a marker of sarcolemmal fragility, is seen 
[131]. Inactivating mutations of the gene coding for calpain-3 cause LGMD2A [116]. 
Calpains are a group of non-lysosomal calcium-dependent cysteine proteases, involved in a 
number of cellular processes, including remodelling of the cytoskeleton, signal transduction 
and apoptosis. Calpain-3 is the muscle-specific member of the calpain family. It has 
additional domains compared to its non-muscle homologues and is mainly localised within 
the sarcomere, where it binds to titin. Calpain-3 is normally present in the sarcomere in an 
inactive form. When activated, it cleaves itself and a number of substrates that includes 
titin, Filamin C, vinexin, ezrin and talin. Its activity is physiologically important for 
maintenance of adult myofibres, probably for turnover of sarcomeric proteins and dynamic 
remodeling of the sarcomere during unloading/reloading cycles of muscle activity. It was 
also shown that calpain-3 deficiency leads to myofibre apoptosis due to IB accumulation 
and consequent loss of NFB-dependent survival genes expression [132]. There is great 
heterogeneity of LGMD2A-associated calpain-3 mutations: some lead to complete lack of 
calpain-3 expression, while others cause loss of enzymatic activity; in other cases, the 
protein is active but mislocalised and yet other patients show impairment of substrate 
cleavage. There seem to be a correlation between type of mutation and phenotype, as null 
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patients tend to show a more severe disease [133]. Despite the observed variability, the 
common mechanism of LGMD2A is a deficiency in calpain-3 proteolytic activity. Calpain-
3 knockout mice suffer muscle atrophy and show misalignment of A-bands [134].
LGMD2B is caused by mutations in dysferlin, a protein involved in sarcolemma repair 
[117]. In exercised fibres, contraction-induced mechanical stress leads to partial disruption 
of the cell membrane, even in the presence of a functional DGC. Resealing of damaged 
sarcolemma is induced rapidly after injury, by a calcium-dependent pathway that requires 
fusion of vesicles near the site of membrane disruption [135]. Dysferlin-deficient mice lack 
this membrane fusion-repair mechanism and develop progressive muscular dystrophy with 
accumulation of vesicles underneath the sarcolemma [136]. Dysferlinopathies also includes 
two other clinically distinct disorders termed Miyoshi myopathy and distal anterior 
compartment myopathy, both of which initially affect distal instead of proximal muscles. 
The coexistence of the three phenotypes of dysferlinopathy in one pedigree has been 
reported, indicating that they are separate manifestations of the same disease [137]. 
LGMD2C-F are also termed sarcoglycanopathies, as they affect one of the sarcoglycans 
[56]. As in DMD, the entire DGC is lost at the sarcolemma, whenever one of the 
sarcoglycans is missing. Clinically, sarcoglycanopathies show predominance of early onset, 
with mean age of onset within the first decade of life, and eventual confinement to a 
wheelchair. However, there is great variability in severity. Patients most often present with 
lower limb weakness and calf hypertrophy, but usually normal cardiac and intellective 
functions, although cardiac involvement has been reported [138]. Respiratory complications 
are frequent. The first animal model of sarcoglycanopathy was a Syrian hamster reported in 
1962 that inherited cardiomyopathy and muscular dystrophy [139]. Loss of δ-sarcoglycan 
was later demonstrated to be the genetic defect of the cardiomyopathic hamster [140]. 
Several sublines of this hamster have been derived since then. More recently, targeted 
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genetic deletion of individual sarcoglycan proteins in mice has been described. α-
sarcoglycan knock-out mice showed progressive muscular dystrophy similar to the mdx
mouse, with extensive degeneration and regeneration of muscle fibres [60]. 
Immunofluorescence analysis demonstrated total loss of α-, β-, γ-, and δ-sarcoglycans and 
sarcospan. Only ε-sarcoglycan was still present at the sarcolemma. This variant, which is 
highly homologous to α-sarcoglycan, can form complexes with β-, γ-, and δ-sarcoglycans in 
smooth muscle, but its role in skeletal muscle is not clear. A later work demonstrated that 
enforced overexpression of ε-sarcoglycan led to the formation of functional sarcoglycan 
complexes and rescued SCGA-/- mice [141]. For what pertains the other components of the 
DGC, only a minor reduction of dystrophin and α-dystroglycan was observed in these mice. 
Nevertheless, association of both α- and β-dystroglycan to the sarcolemma was greatly 
affected. Similarly to mdx mouse, utrophin was up-regulated in α-sarcoglycan null mice. 
Similar findings were reported for β-, γ- and δ-sarcoglycan-deficient mice [59, 142, 143]. 
These data altogether demonstrate that the integrity of the whole DGC is dependent on the 
expression of each sarcoglycan. 
The Z-disc protein telethonin is the target of frameshift mutations that create a premature 
stop codon and cause LGMD2G [122]. Telethonin, also known as T-Cap, is a titin capping 
protein at the Z-disc of the mature sarcomere, where it also interacts with FATZ-1, MLP 
and other proteins. During myofibrillogenesis, telethonin co-localises with titin M-band 
region and is phosphorylated by the titin kinase domain [43]. LGMD2G is a mild form of 
MD with mixed proximal/distal presentation and age of onset between 2 and 15 years. 
Ultrastructural analysis of LGMD2G muscle indicated that sarcomeric architecture integrity 
was maintained. Interestingly, mutations that alter telethonin binding to titin are associated 
with cardiac diseases [144]: impaired binding causes dilated cardiomyopathy (DCM), 
whereas stronger interaction leads to hypertrophic cardiomyopathy (HCM). No knockout 
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model for telethonin has been reported yet. However, MLP-null mice were shown to have 
mislocalised telethonin in the Z-discs of the myocardium and were afflicted by both skeletal 
muscle and heart performance deficit [44].  
LGMD2H was recently linked to mutations in the TRIM32 gene, which encodes for a 
protein involved in the ubiquitin-proteasome degradation pathway. Trim32 is an E3-
ubiquitin ligase with anti-apoptotic properties, its overexpression is associated to cancer 
development [145]. Hence, it is possible that inactivating mutations in LGMD2H affect 
survival signals in myocytes. Moreover, Trim32 ubiquitinates actin, suggesting its 
involvement in myofibrillar protein turnover. The same missense mutation (D487N) was 
identified in patients suffering from sarcotubular myopathy, which therefore can be 
considered as a clinical variant of LGMD2H [123]. 
LGMD2I belongs to the group of diseases caused by loss of the linkage between the 
extracellular matrix and the actin cytoskeleton, such as the sarcoglycanopathies. Mutations 
in the gene encoding fukutin-related protein (FKRP) cause LGMD2I as well as various 
forms of CMD with mental retardation [124, 146], of which CMD1C (congenital muscular 
dystrophy type 1C) is the most severe disorder, with very early onset. FKRP is a 
glycosyltransferase involved in the O-linked glycosylation of α-dystroglycan. Accordingly, 
patients have a marked reduction of α-dystroglycan at the sarcolemma [147]. The same 
deficit of α-dystroglycan processing has been observed in Fukuyama CMD (FCMD) and 
muscle-eye-brain disease (MEB), both caused by mutations in glycosyltransferases. 
Biopsies can also reveal a secondary deficiency in laminin-α2. The data in literature suggest 
a correlation between the reduction in α-dystroglycan and the clinical phenotype in 
MDC1C and LGMD2I, supporting the hypothesis that dystroglycan plays a central role in 
the pathogenesis of these disorders. Additional LGMD forms with mental retardation have 
been recently shown to be allelic to CMDs with defective dystroglycan O-glycosylation. In 
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particular, LGMD2K is caused by mutations in the POMT1 gene [126], LGMD2M is 
characterised by fukutin mutations [128], while LGMD2N and LGMD2O are associated 
with mutations in POMT2 and POMGNT1 proteins, respectively [129, 130]. Together with 
LGMD2I, these disorders are now collectively referred to as dystroglycanopathies. 
The giant sarcomeric protein titin is mutated in LGMD2J and in tibial muscular dystrophy 
(TMD), an autosomal dominant distal myopathy [125]. Furthermore, individuals with 
Edström disease were shown to carry a mutation in titin , therefore all three these diseases 
are considered allelic [148]. Mutations causing TMD/LGMD2J (also referred to as 
titinopathy) normally cluster at the M-line portion of titin, and affect one of the two calpain-
3 binding sites of titin. Indeed, secondary deficiency of calpain-3 is a common feature of 
titinopathies. Integrity of the sarcomere is preserved, but myocytes show signs of apoptosis, 
suggesting that the sensor/signalling function of titin may be damaged in this disease. 
Defects in titin are also associated with cardiomyopathy, but in this case the mutations are 
located more N-terminal, before the M-line region. A natural model of titinopathy is the 
muscular dystrophy with myositis (mdm) mouse, harbouring a deletion of 83 aminoacids 
from the first calpain-3 binding site in I-band titin [149]. The mdm mouse shows the same 
loss of calpain-3 seen in human patients. Titin knockouts die embryonically, indicating that 
functional titin is indispensable during development. In contrast, conditional deletion of M-
line exons in adult striated muscle leads to severe myopathy, with progressive disassembly 
of the sarcomeres in skeletal muscle and widened M-line in cardiomyocytes. Consequently, 
the mice show both skeletal and cardiac involvement and die within 5 weeks of age [150]. 
In line with these studies, expression of a truncated titin in a myofibroblast cell line leads to 
defective myofibril assembly [151]. 
Finally, LGMD2L was recognised in 2007 as a later evolution of patients initially 
diagnosed with quadriceps myopathy [152] and has recently been linked to Anoctamin 5 
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[127], also known as TMEM16E or GDD1. Anoctamins are Ca++-activated Cl- channels 
with eight transmembrane segments. In particular, Anoctamin 5 is highly expressed in 
cardiac and skeletal muscle as well as in bone and was previously found to be mutated in 
patients affected by a bone fragility syndrome called gnathodiaphyseal dysplasia [153].  
5.5. Congenital myopathy 
Congenital myopathies (CM) include a series of both dominant and recessive, slowly 
progressive disorders, usually apparent at birth, that cause general muscle weakness and 
loss of muscle tone and bulk [154]. The distinctive feature of CMs is the accumulation of 
protein aggregates in the cytoplasm [155]. The aggregated material can have tubular, 
filamentous or other morphologies, depending on the type of disease. Major CM forms 
include nemaline myopathy (NM), central core disease (CCD), actin myopathy, and 
myotubular myopathy. 
Typical NM is characterised by intracellular thread- or rod-like bodies. NM presents with 
early weakness of the facial, neck, respiratory and proximal limb muscles, with a later distal 
involvement. More severe forms are rare. Seven loci for NM have been established [94, 
156]: TPM2 (β-tropomyosin), TPM3 (α-tropomyosin), NEB (nebulin), ACTA1 (α-actin), 
TNNT1 (slow troponin T), CFL2 (cofilin-2), and an unknown gene located on chromosome 
15q. It clearly appears that NM is a thin-filament-associated disease. NM-associated 
aggregates, called nemaline rods, are composed essentially of filamentous actin, but also 
contain α-actinin, nebulin and myotilin.
CCD causes skeletal deformities and diffused weakness and is caused by mutations in the 
gene encoding for ryanodine receptor 1, a sarcoplasmic reticulum Ca2+ release channel. It is 
characterised pathologically by the presence of so-called central core lesions, regions of 
sarcomeric disorganization, absence of mitochondria and of oxidative activity [157]. A 
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variant of CCD, known as multi-minicore disease, is caused by alterations in the same gene 
or in selenoprotein N1, and is characterised by multiple, smaller core lesions. 
Myotubular myopathy is caused by defects in myotubularin, a lipid phosphatase that acts on 
phosphatidylinositol 3-monophosphate (PI3P) and has been shown to be essential for 
skeletal muscle maintenance in mice. Myotubular myopathy patients generally have a poor 
prognosis and suffer an early death, due to diminished respiratory capacity, unless 
ventilated [158]. 
Centronuclear myopathy includes both dominant and recessive forms, with mutations in the 
genes encoding dynamin-2 and amphiphysin, respectively [94]. 
Additional CM variants are known to be caused by defects in myosin heavy chain, MyBP-
C, tropomyosin 2, contactin, titin, TRIM32. 
5.6. Myofibrillar myopathy 
Myofibrillar myopathy (MFM) is a relatively broad term comprising various muscle 
diseases that show a variety of intracellular inclusions that appear to be of Z-disc origin and 
are associated with myofibrillar degeneration [159]. In fact, the unifying feature of MFM is 
the dissolution of myofibrils and the abnormal aggregation of disorganised sarcomeric 
material in the sarcoplasm. Protein deposits may appear as amorphous, granular, spherical, 
or polymorphous hyaline structures. These disorders are also termed desmin-related 
myopathies, as they were initially described by accumulation of desmin-positive inclusions 
[155, 160]. However, several additional myofibrillar proteins are found in MFM aggregates, 
including actin, myosin, nebulin, titin, α-actinin, myotilin: basically, all major myofibrillar 
components, reflecting the destruction of the sarcomere [161]. At present, mutations in the 
genes encoding for desmin, selenoprotein N1, αB-crystallin, four-and-a-half-LIM protein 1 
(FHL1) and the sarcomeric proteins myotilin [162], ZASP [163] and Filamin C [164], are 
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known to cause MFM. The majority of patients, however, carry mutations in other 
unidentified loci. Clinically, MFM is heterogeneous, often showing late onset and distal 
muscle involvement, although proximal weakness has been reported in many cases. In 
addition, cardiac and neurological symptoms are frequent in MFM. Other symptoms are 
specific to the gene involved: spine rigidity is associated to selenoprotein N1 mutations, 
whereas cataract is often found in patients carrying αB crystallin defects. 
In 2005, Sharma and Goebel [155] proposed to unify MFMs and CMs under the general 
class of protein-aggregate myopathy (PAM), since they share morphological hallmarks 
(intracellular inclusion bodies). 
5.7. Distal myopathy 
Mutations in several genes are known to be the causative defect in various non-congenital 
myopathies with predominant distal involvement and presenting with variable severity. 
Many of these disorders are allelic forms of other muscle diseases described in this review, 
such as LGMD (mutated genes include myotilin, dysferlin [Miyoshi myopathy], titin 
[TMD] and caveolin-3), CM (nebulin, dynamin-2) and MFM (ZASP). Unique types of 
distal myopathy are Nonaka myopathy, caused by mutations in N-acetylmannosamine
kinase, and Vocal Cord and Pharyngeal Distal Myopathy (VCPDM), which maps to 5q31 
and was therefore thought to be caused by myotilin defects, but no mutations have been 
found [165]. 
5.8. Myotilinopathy 
The first mutation in myotilin gene was discovered in a large American kindred with 
LGMD1A [110] and caused the substitution of an isoleucine for a threonine in the N-
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terminal serine-rich region of the protein (T57I). This mutation does not affect binding to α-
actinin, nor myotilin localisation within the sarcomere. It is likely that the mutation causes a 
gain of function, since LGMD1A shows dominant inheritance. This hypothesis is supported 
by the finding that truncated myotilin constructs have dominant-negative effects on 
myofibril structure in transfected myoblasts [63]. A second mutation was subsequently 
observed in another family [166], affecting the same serine-rich region (S55F). 
Interestingly, both substitutions change a polar, potentially phosphorylable residue (Ser or 
Thr) to a hydrophobic one (Ile or Phe). Emphasising the importance of the Ser-rich domain, 
additional mutations (S60C, S60F, S95I, as well as the previously known S55F) were later 
identified in MFM [162]. LGMD1A and myotilin-related MFM share common molecular 
features, such as Z-line streaming, rimmed vacuoles and accumulation of fibrillar material 
in the myofibres (Figure 5). Clinically, although similar, the two diseases remain distinct 
entities. LGMD1A patients usually present with proximal weakness that can progress to 
involve distal limb muscles and have nasal dysarthric speech. In contrast, MFM patients 
present with more distal than proximal involvement. Moreover, cardiomyopathy is rare in 
LGMD1A individuals, whereas it is often associated with MFM [64]. Furthermore, MFM 
patients are frequently affected by peripheral neuropathy. However, the discovery of 
myotilin mutations (including novel mutations K36E and Q74K) in patients showing both 
LGMD1A and MFM phenotypes led to a common molecular classification under the name 
of myotilinopathy [167]. Another family with mixed proximal and distal myopathy has been 
recently shown to carry a S60F myotilin mutation [168]. The affected members have no 
other phenotypic sign of LGMD1A or MFM, indicating that myotilinopathy has a broader 
clinical spectrum than previously thought. Confirming this finding, a family with myotilin 
S55F substitution was shown to have almost exclusive distal involvement in all affected 
members [169]. 
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Very recently, a novel mutation in the second immunoglobulin-like domain was described 
in a Japanese patient with classical LGMD1A [170], carrying an R405K mutation that 
causes defective homodimerisation and weaker α-actinin binding. 
Another neuromuscular disease, called spheroid body myopathy (SBM), was shown to 
harbour a mutation in the serine-rich domain of myotilin (S39F). SBM has been described 
in only one family [171]. Affected individuals show late onset symptoms quite similar to 
classical LGMD1A. However, a unique pattern of spheroid bodies within the cytoplasm of 
type I fibres was found, which have not been reported in LGMD1A. Rather, they are 
consistent with the amorphous deposits observed in MFM biopsies. In this regard, SBM can 
be viewed as a bridge between other myotilinopathies, as it shares clinical features with 
LGMD1A but shows morphological abnormalities typical of MFM. 
More recently, strong myotilin immunoreactivity was found in nemaline rods and central 
core lesions, the large protein aggregates that are typical of nemaline myopathy and central 
core disease [172]. No mutations have been detected in MYOT gene in these patients. The 
presence of myotilin in both types of protein accumulation may suggest a role in the 
formation or maintenance of such material. 
To recapitulate the phenotype of myotilinopathies, a transgenic mouse model has been 
generated, expressing human myotilin carrying the LGMD1A-associated mutation T57I. 
These mice showed many of the features observed in patients, such as Z-line streaming, 
muscle weakness and myofibrillar aggregation [173]. Moreover, centrally located nuclei 
were observed, indicating regeneration and replacement of damaged myofibres. Protein 
aggregates derived from degenerating myofibrils contained transgenic myotilin, as well as 
endogenous α-actinin, γ-filamin, desmin, titin and myosin proteins. A similar pattern of 
protein aggregation has been described in muscles from MFM and SBM patients. 
52
An interesting observation derives from a non-pathological situation. Exercise-induced 
myofibrillar damage leads to severe pain in non-diseased muscles. This is normally 
associated with Z-disc streaming. Interestingly, myotilin accumulation has been observed at 
sites of active myofibrillar remodelling in exercised muscles, once again indicating a 
prominent role of myotilin in sarcomerogenesis [174]. 
Figure 5. Morphological features of myotilinopathy. Intracellular deposits are revealed by 
Gomori trichrome stain (a) of myofibres from a MFM patient [162]. Desmin (b), αB-
crystallin (c) and other myofibrillar proteins (not shown) accumulate in regions of abnormal 
trichrome staining. (d) Section of LGMD1A muscle [110] showing variations fibre size, 
fibre splitting, centrally located nuclei and rimmed vacuoles (arrows). Electron-microscopy 
images show the vacuoles (e) and characteristic Z-line streaming (f). In (g) another electron 
micrograph showing Z-disc smearing. 
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AIMS OF THE STUDY 
The sarcomere is a highly ordered structure that maintains skeletal muscle integrity and is 
essential for force transmission throughout the muscle fibre. As a consequence, the 
sarcomere is composed of hundreds of proteins, whose expression and localisation is tightly 
regulated. Whenever one of its components is altered or missing, a pathogenic condition 
ensues. Myotilin is an actin cross-linking sarcomeric protein that is mutated in LGMD1A, 
MFM and SBM. Despite growing knowledge of its biology, its role in muscle development 
and function is still poorly understood. This work was undertaken in order to elucidate the 
mechanisms that underlie myotilin-related diseases. 
Specific aims of these studies were: 
1. To characterise myotilin gene and its promoter in mouse. 
2. To analyse the expression pattern of myotilin during mouse development and 
compare it with that in human.  
3. To generate a myotilin-null genetic model in the mouse and analyse its phenotype. 
The result obtained should give important hints on the biological role of myotilin within the 
sarcomere. 
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MATERIALS AND METHODS 
Antibodies used in the study 
Three myotilin-specific antibodies were raised in rabbits in our laboratory and used for 
these studies. Polyclonal antibody #353 was generated using a peptide corresponding to 
residues 353-369 (within the second Ig-like domain) of human myotilin as an antigen. The 
antibody #231 was raised against a GST-tagged fragment spanning amino acids 231–342 
(corresponding to the first Ig loop) of human myotilin. These two antibodies against human 
sequences cross-reacted with mouse myotilin. Finally, antibody #151 was raised against 
purified His-tagged N-terminal mouse myotilin (amino acids 1–150). All antibodies were 
affinity purified using mouse myotilin coupled to Sepharose 4B resin. Titin-specific 
antibody was provided by Prof. Jacques Beckmann (Généthon Laboratory, Evry, France; 
[175]). Anti-α-actinin monoclonal antibody (clone EA-53) was purchased from Sigma-
Aldrich; anti-myosin heavy chain antibody (MF20) was a kind gift of Dr. Marianne Tiainen, 
University of Helsinki. Other antibodies employed were: mouse polyclonal anti-telethonin, 
rat polyclonal anti-FATZ, mouse anti-ZASP, mouse monoclonal anti-β-tubulin clone B-5-1-
2, anti-actin (AC40), and anti-palladin rabbit antibody, (E1a, kindly provided by Markus 
Moser from Max Planck Institute, Germany). 
Cloning of mouse myotilin 
To isolate the mouse orthologue of myotilin, the human full-length cDNA was used as a 
probe to screen a mouse cDNA library. A positive clone representing the partial mouse 
sequence was identified and used for second-round screening at higher stringency. Finally, 
full-length mouse myotilin cDNA was isolated and sequenced. RACE analysis was 
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performed in order to detect the 5’-end of mRNA, using a myotilin-specific reverse primer 
for first strand cDNA synthesis. 
Long-range touchdown PCR was used to determine the genomic structure of mouse 
myotilin gene, based on homology with the human locus. Genomic DNA was extracted 
using a standard method [176] and amplified using the following protocol: after initial 
template denaturation (5 minutes at 94°C) four miniprograms of four cycles each were run 
(94°C, 30 sec; annealing step, 30 sec; 68°C, 4 min) with annealing temperatures 62, 60, 58, 
and 56°C, followed by 32 standard cycles (94°C, 30 sec; 55°C, 30 sec; and 68°C, 4 min). 
PCR products were purified from agarose gel and sequenced to determine exon/intron 
boundaries. 
In situ hybridisation 
A non-radioactive method was employed to study myotilin mRNA levels in developing and 
adult mouse tissues. Two fragments of myotilin cDNA (nucleotides 531-1056 from the 
coding region and 1614-2150 from the 3’-untranslated region) were amplified by PCR and 
cloned into a pBluescript-based vector, with T3 and T7 promoters on either side of the 
insert. In vitro transcription from T3 and T7 sites in the presence of digoxigenin-UTP 
allowed the synthesis of sense and antisense digoxigenin-labelled RNA probes. Antisense 
probes were used to detect myotilin RNA, while sense transcripts were used as negative 
controls. Pregnant female mice were sacrificed and embryos and adult organs were 
dissected according to approved procedures and fixed in 4% paraformaldehyde, dehydrated 
in ethanol and xylene and embedded in paraffin. Four micrometer sections were placed on 
glass slides, paraffin was removed and tissues rehydrated. Subsequently, the samples were 
treated with 0.3% Triton X-100 and proteinase K and hybridised overnight with RNA probe 
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in hybridisation buffer (40% formamide, 10% dextran sulfate, 1X Denhardt’s solution, 4X 
SSC, 10 mM DTT, plus yeast tRNA and salmon sperm DNA as blocking agents). After 
extensive washes, the probe was detected by alkaline phosphatase-conjugated anti-
digoxigenin antibody. In some cases, samples were counterstained with hematoxylin. A 
titin-specific probe was obtained from Prof. Siegfried Labeit (University of Heidelberg, 
Germany) and used as a control for muscle-specific staining. 
Immunochemistry 
For immunohistochemistry, tissue specimens were snap-frozen in isopentane chilled with 
liquid nitrogen and stored at -80°C. Cryostat sections were mounted on glass slides, air-
dried and stored at -80°C until needed. C2C12 cells were directly grown on glass coverslips, 
induced to differentiate by shifting the culture to medium containing 2% horse serum and 
finally fixed with methanol and mounted onto glass slides. 
Tissue sections and cell specimens were stained with the specific antibody, or the 
corresponding pre-immune serum as a control, in the presence of 3% BSA as a blocking 
agent, and then incubated with a species-specific secondary antibody. Bound antibodies 
were detected with Vectastain Elite ABC kit and the slides were counterstained with 
haematoxylin and eosin. 
Myofibrils were isolated from skeletal muscles as described [177], centrifuged on glass 
slides, fixed with methanol and incubated with specific primary antibody. FITC- or TRITC-
conjugated secondary antibodies were visualised by fluorescence microscope. 
For Western blotting, tissues were homogenised in reducing Laemmli buffer using an Ultra- 
Turrax® homogeniser and the lysates were run on SDS–PAGE, transferred to nitrocellulose 
membranes and probed with the various antibodies. 
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Promoter characterisation 
A Bacterial Artificial Chromosome (BAC) comprising the mouse myotilin locus was 
isolated from a mouse genomic library prepared from 129/SvJ mouse DNA (Research 
Genetics) using a full-length cDNA as a probe. The promoter region was cloned from the 
BAC DNA and sequenced. Analysis of putative transcription factor binding sites within the 
promoter sequence was performed with MatInspector software and with the TESS database. 
A number of progressively deleted fragments from this region were cloned into the 
pGL3basic vector, upstream of the firefly luciferase gene. To study promoter activation 
during myoblast differentiation, C2C12 cells were seeded in 6-well plates, induced to 
differentiate, and co-transfected with the reporter constructs and the pRL-TK control 
plasmid (for internal sample normalisation). The cells were then lysed at different times and 
assayed for luciferase activity. 
Generation of knockout mice 
Conditional deletion of myotilin gene was achieved by replacing the endogenous locus with 
a floxed allele, in which exon 3 was flanked by loxP sites, that can be induced to recombine 
by expression of Cre recombinase, thus deleting the flanked sequence. The targeting vector 
carries the Neomycin resistance gene for selection of homologous recombination events, 
and the Herpes simplex virus thymidine kinase (HSV-tk) marker for negative selection of 
incorrect recombination. The construct was electroporated into R1 embryonic stem (ES) cell 
line, of 129Sv genetic background. After electroporation, G418- and ganciclovir-resistant 
ES clones were tested for correct targeting by Southern blotting, using 5’ and 3’ external 
probes. Chimeric embryos were produced by aggregation of targeted ES cells with morula 
stage wild-type embryos of ICR strain. Two chimaeras were identified that passed the 
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floxed allele through the germ line. Heterozygous floxed mice (myofx/+) were crossed with 
Cre-mice, ubiquitously expressing Cre recombinase under the cytomegalovirus promoter, to 
generate myo-/+ offspring carrying the deleted allele, which were then interbred to obtain 
homozygous myotilin knockout mice (myo-/-). The mice were subsequently bred on a mixed 
129SvJ/ICR background for analysis. 
Phenotypic analysis of myo-/- mice 
For morphological analysis, muscle specimens were dissected and frozen in nitrogen-chilled 
isopentane. Five μm cryostat sections were placed on silanized glass slides, fixed with 
acetone and stained with haematoxylin and eosin. For ultrastructural studies, muscles were 
fixed in 4% phosphate buffered glutaraldehyde, dehydrated and embedded in epoxy resin. 
Ultra-thin sections were post-stained with uranyl acetate and lead citrate. 
Mice were weighed weekly from birth for 11 weeks and then monthly until 38 months of 
age. Spontaneous behaviour was monitored throughout life. Muscle strength was tested 
using a grip strength meter. The mouse is placed in front of a grasping bar. The animal 
instinctively grabs the bar as it is pulled backwards. The instrument records the peak pull 
force, when the mouse releases its grip. The strength was normalised according to the 
weight. Voluntary running was measured in cages containing small metal running wheels 
connected to digital magnetic counters. The mice were allowed free access to the wheel. 
Running activity was recorded for a total period of 5 weeks. The parameters collected were 
daily running time and distance. At the end of the exercise, the mice were sacrificed and 
skeletal muscles were collected and prepared for cryosectioning. 
For analysis of sarcolemma integrity, the mice were injected intraperitoneally with 1 mg of 
Evans Blue dye (EBD, a fluorescent dye that cannot enter intact cells) in 0.1 ml PBS per 10 
g of body weight and euthanized by cervical dislocation 6 hours later. The muscles were 
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dissected and rapidly frozen in nitrogen-cooled isopentane. Cryostat sections were fixed and 
observed with a fluorescence microscope. 
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RESULTS AND DISCUSSION 
Mouse myotilin gene characterisation (I) 
Analysis of the mouse myotilin gene demonstrated a high degree of conservation between 
human and mouse. The coding sequences are 80% identical and amino acid sequences show 
90% identity and 94% similarity, when considering conservative changes (I, Fig. 1). The 
mouse genomic locus is localised in a syntenic region (murine 18 B3 corresponding to 
human 5q31) and its overall exon/intron structure is conserved; the first exon comprises 
only untranslated sequence, while start and stop codons are located on exons II and X, 
respectively (I, Fig. 1, Table 1). PCR analysis of the transcript revealed three isoforms in 
mouse skeletal muscle tissue, two of which are predicted to encode for the same 
polypeptide. The third, smaller mRNA isoform lacks the upstream translation start codon: 
although another in-frame ATG is present, no smaller protein form was detected by Western 
blotting. The significance of such deleted mRNA in vivo is not clear. Northern blot analysis 
confirmed the presence of one major myotilin mRNA band, mainly in skeletal and cardiac 
muscle (I, Fig. 2). Minor expression was also found in other tissues, such as lung, kidney 
and liver. Localisation of myotilin transcript within the tissues was further studied by in situ 
hybridisation. Apart from strong staining of striated muscles, expression was identified in 
the bronchial epithelium, the cortical region of the kidneys, as well as various structures of 
the central nervous system, such as the hippocampus, the olfactory bulb and Purkinje cells 
(I, Fig. 3). A particularly high signal was detected in peripheral ganglia. Human myotilin 
has also been shown to be expressed in nerves [73]. These data may explain peripheral 
neuropathy observed in MFM patients. The fact that this was not found in LGMD1A 
families raises interesting questions concerning the phenotypic variability of 
myotilinopathy. However, absent or diminished tendon reflexes in LGMD1A patients could 
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suggest an incipient peripheral neuropathy. Also, cardiomyopathy is not a constant 
manifestation of myotilinopathies. 
Interestingly, no myotilin was detected in smooth muscles, in keeping with its suggested 
role in the organisation of the sarcomere. Strong association of myotilin with 
sarcomeric/cytoskeletal structures was also indicated by its high resistance to detergent-
mediated extraction (I, Fig. 4), and its ability to induce actin bundles when over-expressed 
in non-muscle cells. 
Analysis of myotilin regulation showed that it is transcribed relatively late in the maturation 
of mouse C2C12 myoblasts: while α-actinin and myosin heavy chain are already up-
regulated 48 hours after induction of differentiation, myotilin expression was not observed 
until day 8 (I, Fig. 5). At this stage, however, myotilin is already correctly positioned along 
the myofibrils, showing the classical cross-striated staining pattern. In agreement with its 
predominant muscular expression, several muscle-specific responsive elements could be 
identified within the promoter region of mouse myotilin gene (I, Fig. 6). The importance of 
such putative transcription factor binding sites was studied by luciferase reporter assays, 
using progressive deletion constructs derived from the promoter sequence. Reporter activity 
was recorded during C2C12 differentiation. Analysis of the data suggested a crucial role for 
one MEF2 binding site and a canonical myogenin/myoD E-box site (both situated 
approximately 1000 bp upstream of the transcriptional start site) which appeared to be 
required for full transcriptional activity (I, Fig. 6). However, we did not observe an all or 
nothing effect of any single region of the promoter. Rather, progressive loss of reporter 
activity was caused by successive deletions. Consistent with late up-regulation of 
endogenous myotilin in differentiating myocytes, highest luciferase activity was detected at 
day 8 post-induction. 
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These data altogether suggest that myotilin function is extremely conserved between human 
and mouse. Gene structure, amino acid sequence, pattern of expression and regulation are 
indeed very similar in the two species. In particular, the residues that are mutated in human 
disease are identical in murine sequence. In addition, this study indicates that myotilin is 
expressed, albeit at very low levels, in various tissues other than striated muscle. This 
finding is corroborated by data from embryonic tissues (see next section) and also by 
database searches (www.ncbi.nlm.nih.gov/UniGene) and previous work [72]. The role of 
myotilin in these cell types is unclear, but is not unprecedented among sarcomeric proteins, 
as exemplified by cellular-titin [178]. Non-muscle myotilin might be involved in the 
organisation of stress fibre structures, since it has potent actin bundling activity and binds to 
stress fibres-associated proteins α-actinin, filamin-A and -B, and CLP-36. However, this 
hypothesis has not yet been experimentally validated. 
Expression of myotilin during mouse development (II) 
We studied the spatial and temporal pattern of myotilin expression during embryonic 
development by in situ hybridisation and immunohistochemistry. As noted above, myotilin 
is mainly expressed in adult striated muscles; however, low levels of myotilin are also 
detected in other tissues, suggesting a broader function. In mouse embryos, its expression is 
even more widespread, in particular during mid-stages of gestation: at E13, strong myotilin 
staining was observed in many tissues including lung, liver, skin, cartilage and most of the 
nervous system (II, Fig. 2 and 3, Table 1). Later (E16-E18), expression in various organs 
declined to lower levels, as observed in the adult. As control experiments, non-specific 
probes or pre-immune serum did not give any signal, while a titin-specific probe only 
labelled skeletal muscles. A similar perinatal down-regulation of expression has been 
described previously, for β-sarcoglycan and palladin [65, 175]. 
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Looking at earlier stages of development, between E8 and E11, myotilin mRNA and protein 
were found in the heart (the first organ to show myotilin expression), in the somites and in 
neural epithelium (II, Fig. 1). In line with in vitro observations (see I, Fig. 5 and [75]), 
expression in the somite was delayed compared to other sarcomeric proteins: while titin is 
already expressed at day 9 post coitum [5], myotilin could not be detected before day 10. 
Interestingly, myotilin in the somite was not restricted to the myotome compartment, as 
normally observed for sarcomeric proteins, but appeared as a more diffuse staining reaching 
the surrounding areas, corresponding to the dermatome and sclerotome, although myotomal 
cells showed the strongest signal. In addition, in cross-sections, the neural tube showed 
myotilin expression. These features were also observed in human embryos, where parallel 
staining with a titin-specific antibody allowed a direct comparison: while titin was 
exclusively detected in the myotome, myotilin was clearly present in a broader area (II, Fig. 
4). Thus, myotilin is similarly regulated in mouse and human embryos, again suggesting 
that the mouse should be a good model for myotilinopathy. 
Deletion of myotilin gene in vivo (III) 
Mutation of myotilin in LGMD1A/MFM patients leads to disruption of the Z-discs, 
illustrating the importance of myotilin function in the maintenance of sarcomere 
architecture. Also, its widespread developmental expression suggested a relevant role in 
mouse development. To study the consequences of myotilin loss in vivo, we generated a 
conditional knock-out mouse model (myo-/-) using Cre-LoxP-mediated gene targeting. We 
chose an inducible system in order to circumvent possible embryonic lethality, which we 
might have expected from the available data. The targeting construct was designed to cause 
Cre-inducible loss of the entire exon 3, which was predicted to create a reading frameshift, 
leading to a premature stop (III, Fig. 1). This would cause nonsense-mediated decay of the 
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mutant mRNA, or drive the synthesis of a non-functional polypeptide missing most of 
myotilin sequence including the two Ig-like domains. Indeed, while exon 3-specific primers 
did not amplify any PCR product from myo-/- mice, primers flanking the targeted exon 
revealed the presence of a deleted mRNA (III, Fig. 1). However, by Northern blotting, no 
myotilin transcript could be detected in null mice, even using an exon 4-5-6-specific probe 
(III, Fig. 2). This is probably due to a lower sensitivity of Northern blotting compared to 
RT-PCR, and suggests degradation of the deleted myotilin transcript. In agreement with 
Northern data, no myotilin protein was expressed in myo-/- skeletal muscle, as assessed by 
Western blotting and immunofluorescece staining (III, Fig. 3, 4). 
Surprisingly, myo-/- mice not only were born at normal mendelian ratio, but appeared 
healthy throughout their lives. Myotilin null mice grew normally, showing no statistically 
significant difference in weight compared to myo+/+ and myo+/- littermates (III, Fig. 5). 
Moreover, no alteration was observed in muscle force and running performance.  
Ultrastructural and morphological analysis of skeletal muscles did not reveal major 
consequences of myotilin absence (III, Fig. 4). The fibres appeared normal, with peripheral 
nuclei; no sign of Z-disc streaming and no cytoplasmic deposits were noted in knock-out 
muscles. No damage in sarcolemma integrity was present. Similarly, we did not see any 
overt abnormality in other organs. Anti-α-actinin and anti-titin immunostaining of 
myofibrils showed a normal cross-striated pattern in both wild-type and null mice, 
indicating that the general structure of the sarcomere is preserved (III, Fig. 4). 
Seeing that there is no obvious phenotypic repercussion of myotilin deletion, we thought 
that subtle compensatory changes in the organisation of the sarcomere might have occurred 
and vicariate the loss of myotilin. Analysis of Z-disc proteins expression revealed a 
significant up-regulation of telethonin, in both skeletal and cardiac muscles, in myo-/- mice 
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(III, Fig. 3). Interestingly, both telethonin and myotilin bind to titin within the Z-disc. Thus, 
telethonin might compensate for myotilin loss in myo-null mice. This may explain why 
absence of myotilin is never observed in human disease. However, the reverse is not true, as 
lack of telethonin leads to LGMD1G. Whether this increase in telethonin expression is 
required for maintenance of muscle integrity in the absence of myotilin, is not clear at the 
moment. Alternatively, telethonin up-regulation could be a sign of stress, as telethonin has 
been shown to be part of a sensor machinery within the Z-disc. Neither palladin nor 
myopalladin, the two closest homologues of myotilin, showed any change in expression 
levels. 
The targeting of other Z-disc proteins, such as FATZ-2 and ALP, did not cause any clear 
skeletal muscle perturbation in mice [179, 180], suggesting that the Z-disc is a highly stable 
structure that is able to sustain specific protein losses. 
Our results indicate that myotilin is not required for mouse development or for adult muscle 
tissue integrity. Combining these data with the current knowledge of myotilin function and 
the pathobiology of myotilinopathies, we suggest that disease-associated myotilin forms 
carry a dominant pathogenic activity, rather than a loss of their normal physiologic role. 
This is in agreement with cellular data, showing that over-expression of a truncated myotilin 
induces the destruction of nascent sarcomeres in differentiating myoblasts [63]. 
Furthermore, in vivo data from transgenic myoT57I and double transgenic wt/T57I mice 
[173, 181] suggest that mutated myotilin may act as a super-active centre of protein 
aggregation, so that, while its normal function stabilises the Z-disc, its hyperactivity (or 
overexpression) destroys it. 
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CONCLUSIONS 
In this work I describe the cloning and characterisation of the mouse myotilin gene. 
Myotilin was identified in our laboratory as an α-actinin binding protein in human striated 
muscle [73]. It was later found to be involved in the onset of muscular disease [110], now 
termed myotilinopathy. This finding prompted us to initiate studies on the mouse 
orthologue, in order to gain insights into the function of myotilin in vivo, using murine 
models. 
Myotilin is highly conserved and similarly regulated between human and mouse (I), which 
is consistent with its role in sarcomere building. Its expression begins at late stages of 
muscle cell differentiation (I-II), suggesting that myotilin is involved in the final alignment 
of myofibrils, rather than in initial assembly of the Z-disc. Over-expression of truncated 
myotilin leads to Z-disc collapse and dominant mutated myotilin in patients causes Z-disc 
streaming and misalignment. Within the Z-disc, myotilin interacts with α-actinin, filamin C, 
actin, FATZ and ZASP. 
Both human [73, 110] and mouse (I) studies identified the presence of two major 
transcripts, and other minor isoforms, but their role is not clear at this stage. It is possible 
that shorter forms of myotilin may regulate localisation and function of the full-length 
isoform. Future work may help elucidate the role of alternative transcripts of myotilin. In 
addition, post-translational modifications of myotilin have not yet been studied. Both in 
mouse and human, myotilin antibodies detected minor bands at higher and lower molecular 
weights. In preliminary experiments, we did not find evidence of N- or O-linked 
glycosylation, nor tyrosine phosphorylation of mouse myotilin (data not shown). However, 
disease-associated mutations very frequently hit serine or threonine residues, strongly 
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suggesting a possible regulation by phosphorylation, which was indeed verified at least in 
vitro [77]. This might open a new line of investigation in myotilin studies. 
The fact that myotilin expression is not tightly restricted to striated muscle, but is found in 
other tissue types (I-II), although at lower levels, indicates that it may have additional 
functions, for example in focal adhesions. The biological meaning of the wide expression 
pattern during development (II) is not understood. It may reflect a function in tissue 
modelling. However, targeted disruption does not prevent normal development of myo-null 
mice (III). Therefore, myotilin does not seem to have a fundamental role in mouse 
development, not even in skeletal muscle formation. Alternatively, its task is backed up by 
other Z-disc proteins. However, even double mutant myotilin-null/200kDa-palladin-
hypomorph animals do not show an overt phenotype, only developing a mild myopathy at 
old age [182]. It will be interesting to engineer a myotilin/palladin/myopalladin triple 
knockout. Indeed, no myotilin loss-of-function mutations have been described in muscle 
disease. Patient-derived mutant T57I, when introduced into transgenic mice, caused a 
LGMD1A/MFM-like phenotype [173], confirming that myotilinopathy is a gain-of-function 
disorder. 
The accumulating knowledge of the functions of myotilin in muscle physiology should help 
understand its role in muscle pathology.  
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